Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 2/20 | 0.45 |
| ▸ | NOS2 | P35228 | 2/20 | 0.45 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.32 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.32 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.32 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 2/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | GBA1 | P04062 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6078728 | 1.00 | SLC6A4 (0.45) | SLC6A4NOS2CACNA1GCACNA1BCACNA1C | |
| SCHEMBL6082710 | 0.91 | SLC6A4 (0.46) | SLC6A4NOS2GPR119AAK1AR | |
| SCHEMBL6079148 | 0.89 | SLC6A4 (0.34) | SLC6A4NOS2CACNA1GCACNA1BCACNA1C | |
| SCHEMBL6077823 | 0.88 | SLC6A4 (0.44) | SLC6A4NOS2CACNA1GCACNA1BCACNA1C | |
| SCHEMBL6079371 | 0.82 | LMNA (0.36) | SLC6A4NOS2CACNA1GCACNA1BCACNA1C | |
| SCHEMBL6079361 | 0.82 | LMNA (0.36) | SLC6A4NOS2CACNA1GCACNA1BCACNA1C | |
| SCHEMBL6079296 | 0.82 | SLC6A4 (0.46) | SLC6A4NOS2GPR119AAK1AR | |
| SCHEMBL6079017 | 0.80 | CACNA1G (0.31) | CACNA1GCACNA1BCACNA1CPDK2 | |
| SCHEMBL6079011 | 0.80 | CACNA1G (0.31) | CACNA1GCACNA1BCACNA1CPDK2 | |
| SCHEMBL6078288 | 0.76 | NOS2 (0.65) | SLC6A4NOS2GPR119AAK1AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7119109-B2 | Heteroarylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase | ASTRAZENECA AB (SE) | 2006-10-10 | — | — | US | disclosed |
| US-20040220234-A1 | Heteroarylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase | ASTRAZENECA AB (SE) | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220234-A1 | Heteroarylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase | NOS3, NOS2, NOS1 | SLC6A4 1543/4885NOS2 2/4885CACNA1G 893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.